Conferences
ASCO GU 2023: Barriers to Guideline-Concordant Use of Bone Modifying Agents for Prostate Cancer
February 16, 2023
ASCO GU 2023: Geographic Variation of Decipher® Genomic Classifier in Patients with Early Prostate Cancer
February 16, 2023
ASCO GU 2023: Effect of Equal Access to Care on Prostate Cancer Progression in Minority Patients
February 16, 2023
ASCO GU 2023: LuCAB: A Phase I/II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with mCRPC
February 16, 2023
ASCO GU 2023: Effect of Cerebral Dopamine Metabolism Genetic Polymorphism on Patient-Reported Quality-of-Life (QOL): An Analysis of the E3805 CHAARTED Trial
February 16, 2023
ASCO GU 2023: The CONFIDENT-P Trial: Clinical Implementation of Artificial Intelligence Assistance in Prostate Cancer Pathology
February 16, 2023
ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study
February 16, 2023
ASCO GU 2023: Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study
February 16, 2023
ASCO GU 2023: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer
February 16, 2023
ASCO GU 2023: A Multi-Center, Prospective, Observational Study of Patients with Prostate Cancer Being Treated with Relugolix: OPTYX
February 16, 2023